Coherus Will Launch US Lucentis Biosimilar By 2021

Deal With Bioeq Pulls Forward Ranibizumab Launch By Two Years

Buoyed by the success of its Udenyca pegfilgrastim biosimilar, Coherus has struck a deal with Bioeq to acquire commercialization rights to its biosimilar version of Lucentis (ranibizumab) in the US, eyeing a launch date of 2021.

Red_Numbers_2021
Coherus has struck a deal that will allow it to launch a biosimilar version of Lucentis by 2021 • Source: Shutterstock

Coherus BioSciences has struck a deal to acquire exclusive rights from Bioeq to commercialize the firm’s proposed biosimilar to Lucentis (ranibizumab) in the US. Swiss biopharmaceutical joint venture Bioeq plans to file a Biologics License Application with the US Food and Drug Administration in the fourth quarter of 2019, with Coherus planning to launch the product in 2021.

Coherus said it would “apply its proficiencies and infrastructure developed for the oncology therapeutic commercial environment to the ophthalmology therapeutic...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business